Sort by
Items per page

Send to

Choose Destination

Search results

Items: 6


Resistance to Antiangiogenic Therapy Is Associated with an Immunosuppressive Tumor Microenvironment in Metastatic Renal Cell Carcinoma.

Liu XD, Hoang A, Zhou L, Kalra S, Yetil A, Sun M, Ding Z, Zhang X, Bai S, German P, Tamboli P, Rao P, Karam JA, Wood C, Matin S, Zurita A, Bex A, Griffioen AW, Gao J, Sharma P, Tannir N, Sircar K, Jonasch E.

Cancer Immunol Res. 2015 Sep;3(9):1017-29. doi: 10.1158/2326-6066.CIR-14-0244. Epub 2015 May 26.


p19ARF is a critical mediator of both cellular senescence and an innate immune response associated with MYC inactivation in mouse model of acute leukemia.

Yetil A, Anchang B, Gouw AM, Adam SJ, Zabuawala T, Parameswaran R, van Riggelen J, Plevritis S, Felsher DW.

Oncotarget. 2015 Feb 28;6(6):3563-77.


Characterization of a synthetic human LINE-1 retrotransposon ORFeus-Hs.

An W, Dai L, Niewiadomska AM, Yetil A, O'Donnell KA, Han JS, Boeke JD.

Mob DNA. 2011 Feb 14;2(1):2. doi: 10.1186/1759-8753-2-2.


The interaction between Myc and Miz1 is required to antagonize TGFbeta-dependent autocrine signaling during lymphoma formation and maintenance.

van Riggelen J, Müller J, Otto T, Beuger V, Yetil A, Choi PS, Kosan C, Möröy T, Felsher DW, Eilers M.

Genes Dev. 2010 Jun 15;24(12):1281-94. doi: 10.1101/gad.585710.


MYC as a regulator of ribosome biogenesis and protein synthesis.

van Riggelen J, Yetil A, Felsher DW.

Nat Rev Cancer. 2010 Apr;10(4):301-9. doi: 10.1038/nrc2819. Review.


Cellular senescence is an important mechanism of tumor regression upon c-Myc inactivation.

Wu CH, van Riggelen J, Yetil A, Fan AC, Bachireddy P, Felsher DW.

Proc Natl Acad Sci U S A. 2007 Aug 7;104(32):13028-33. Epub 2007 Jul 30.

Supplemental Content

Support Center